The Role and Challenges of Academia in the Marine Natural Products Pipeline

The ocean holds a vast, largely untapped library of chemical recipes. For decades, scientists have known that marine creatures—from sponges and sea squirts to microscopic bacteria living on the seafloor—produce unique molecules that can kill cancer cells, fight bacteria, or stop pain. These molecules, known as marine natural products, are the raw material for new medicines. The path from finding a promising molecule in a jar to having it on a pharmacy shelf is long and expensive. It involves screening thousands of samples, testing them in animals, and running rigorous safety trials in people. While universities and public research labs are excellent at the first steps of this journey, discovering and describing these new compounds, very few ever make it to the final stage of becoming an approved drug.

This gap between discovery and a marketable medicine is the focus of a new study by researchers from institutions in Belgium, the United Kingdom, and the United States. The team wanted to understand why so many promising marine compounds stop moving forward. Instead of looking at the projects that are still running or the few that succeeded, they chose to examine six specific projects that had already stalled or failed. By interviewing the scientists who worked on these halted projects, the researchers sought to uncover the real reasons the work stopped. They found that the problem was rarely that the science itself was wrong. Instead, the projects usually died because of practical hurdles: a lack of money to keep going, complex rules about collecting samples from the ocean, and a disconnect between what universities are rewarded for and what the pharmaceutical industry needs to succeed.

The study began by reconstructing the history of six distinct marine drug projects, each of which had reached a point where work ceased. The researchers interviewed sixteen people who had been directly involved in these efforts, including academic chemists, biologists, and collaborators from industry and government. They asked these participants to walk them through the timeline of their work, focusing on the specific moments when decisions were made to stop, pause, or change direction. The goal was not to judge the science but to understand the ecosystem in which that science lived. The researchers organized the barriers they heard about into five main categories: a shortage of resources, friction with rules and regulations, a mismatch with the market, difficulties in translating knowledge from one group to another, and conflicting incentives for the scientists involved.

The most common obstacle reported was simply a lack of resources. In the early stages of research, scientists often have enough material to test a compound in a petri dish. However, moving to the next stage requires vastly larger quantities of the substance to test in living animals and eventually in humans. For marine compounds, obtaining these larger amounts is notoriously difficult. Unlike plants that can be grown in a field, many marine organisms are hard to collect in large numbers without harming the ecosystem, and they are often difficult to grow in a lab. One researcher described the situation as having a "scarce amount" that was fine for small-scale work but became a major stressor when the project needed to scale up. Without a reliable way to produce more of the compound, the project hits a wall. This scarcity is compounded by funding gaps. Grants often cover the initial discovery but do not provide the sustained capital needed to bridge the gap to clinical trials, leaving promising leads stranded.

Beyond the physical lack of material, the researchers found that navigating the rules of the road was a massive drain on time and energy. Collecting marine samples involves a complex web of international regulations regarding access and benefit sharing. These rules are designed to ensure that countries where the samples are collected receive a fair share of the benefits if a drug is developed from them. While necessary, the process of securing permits and negotiating agreements often takes months or even years. One participant noted that their project received approval for a material transfer agreement four months after the work had already started, a delay that consumed valuable time and momentum. Furthermore, the legal requirements for patents create a separate set of challenges. Academics are often encouraged to publish their findings quickly, but publishing a discovery before securing a patent can start the clock on the patent's expiration. Since developing a drug takes many years, a patent filed too early might expire before the drug ever reaches the market, leaving the company with no financial incentive to continue the work.

The study also highlighted a cultural divide between the world of academic research and the world of commercial drug development. Universities typically reward scientists for publishing papers in scientific journals, which is a sign of success in academia. However, the pharmaceutical industry looks for different outcomes: a safe, effective drug that can be manufactured and sold. This misalignment means that a project might be considered a success by the university because it produced a publication, even if the compound never moved closer to becoming a medicine. The researchers found that many projects ended not because the science failed, but because the team could not find a partner or funding source willing to take the next step. In several cases, industry partners decided to shelve a compound not because it didn't work, but because it didn't fit their current business strategy or portfolio.

Despite these failures, the researchers emphasized that these halted projects were not wasted efforts. Even though the compounds did not become drugs, the work generated significant value. Every project produced new knowledge, such as a better understanding of how a specific marine organism works or a new way to synthesize a molecule. Some projects created "option value," meaning they secured patent rights that kept the door open for future development, even if the current team could not proceed. Others produced "use value," where the compounds were used as tools by other scientists to study diseases or test new methods. The study suggests that the value of these projects is often bounded by the barriers they faced, rather than by the quality of the science itself. When a project stops, it is often because the handoff from discovery to development failed, not because the discovery was flawed.

To address these issues, the authors propose several targeted interventions that focus on the points where the system breaks down. They suggest that funding models should be more flexible, allowing money to be redirected within a large research group from a stalled project to a more promising one, rather than letting the funds disappear. They also call for shared resources, such as a dedicated expert on access and benefit-sharing regulations who could help multiple research groups navigate the complex legal landscape. Additionally, the researchers advocate for better training for scientists in the practical aspects of drug development, including how to manage patents and how to communicate with industry partners. By strengthening the connections between the academic discovery phase and the later stages of development, the scientific community can better ensure that the potential of the ocean's chemical library is not lost to bureaucratic and economic hurdles.

The findings of this study serve as a reminder that the journey from the ocean to the pharmacy is not just a scientific challenge, but a logistical and systemic one. The ocean contains a wealth of potential cures, and the scientists who study them are capable of finding them. However, the path forward requires more than just discovery; it requires a system that supports the long, difficult transition from a laboratory finding to a medicine that can help patients. By understanding exactly where and why projects stop, researchers and policymakers can begin to build a more resilient pipeline, ensuring that the next generation of marine medicines has a better chance of reaching the people who need them.